<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117556</url>
  </required_header>
  <id_info>
    <org_study_id>17.0315</org_study_id>
    <nct_id>NCT03117556</nct_id>
  </id_info>
  <brief_title>Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer</brief_title>
  <official_title>Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norton Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the efficacy of bilateral thoracoscopic splanchnicectomy (BTS) to&#xD;
      conventional narcotic analgesia for control of abdominal pain in patients with pancreatic&#xD;
      ductal adenocarcinoma not amenable to surgical resection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients with unresectable pancreatic cancer will be considered for participation in this&#xD;
      study. Patients with locally advanced or metastatic cancer that meet inclusion criteria will&#xD;
      be randomized into one of two arms, treatment with BTS and narcotic analgesia or treatment&#xD;
      with narcotic analgesia alone. After randomization a baseline pain score will be assessed&#xD;
      using the visual analog pain scale. Narcotic dosage and frequency will be evaluated at the&#xD;
      time of enrollment. A pre-treatment quality of life score will be recorded using the SF-12®&#xD;
      Patient Questionnaire. Patients will also be queried about the presence of nausea and reflux.&#xD;
&#xD;
      After all baseline assessments are complete patients will be taken to the OR to undergo their&#xD;
      assigned procedure. BTS and infusaport placement will be performed on patients randomly&#xD;
      selected for treatment with BTS and narcotic analgesia. BTS will be performed as described in&#xD;
      the study procedure. Patients chosen to be treated with narcotic analgesia alone will undergo&#xD;
      infusaport placement only. An evaluation will be completed postoperatively in which the&#xD;
      length of stay, post-op complications, and chest X-ray results will be recorded. Follow-up&#xD;
      assessments will be conducted 24-48 hours post-procedure and at the time of discharge.&#xD;
      Further follow-up assessments will be conducted 14 days, 30 days, and 90 days post-procedure&#xD;
      during an office visit with the clinical research team or medical oncology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no subjects enrolled&#xD;
  </why_stopped>
  <start_date type="Actual">August 31, 2017</start_date>
  <completion_date type="Actual">April 16, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 16, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All patients with unresectable pancreatic cancer will be considered for participation in this study. Patients with locally advanced or metastatic cancer that meet inclusion criteria will be randomized into one of two arms, treatment with BTS and narcotic analgesia or treatment with narcotic analgesia alone.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abdominal pain</measure>
    <time_frame>1 year</time_frame>
    <description>Pain will be measured using a visual analog pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Narcotic Requirements</measure>
    <time_frame>1 year</time_frame>
    <description>Narcotic usage will be monitored at each follow-up visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of Life will be measured using the SF-12® Patient Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Nausea</measure>
    <time_frame>1 year</time_frame>
    <description>Patients will be queried about the presence of nausea using a questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Reflux</measure>
    <time_frame>1 Year</time_frame>
    <description>Patients will be queried about the presence of reflux using a questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Anti-emetics</measure>
    <time_frame>1 year</time_frame>
    <description>anti-emetic dosage will be measures at each follow-up visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Unresectable Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>BTS Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilateral thoracoscopic splanchnicectomy and infusaport placement will be performed on patients randomly selected for treatment with BTS and narcotic analgesia. Narcotics will still be prescribed for pain as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No BTS Intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients chosen to be treated with narcotic analgesia alone will undergo infusaport placement only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bilateral Thoracoscopic Splanchnicectomy</intervention_name>
    <description>BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.</description>
    <arm_group_label>BTS Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be 18 years of age&#xD;
&#xD;
          2. Diagnosed with stage III/IV pancreatic cancer&#xD;
&#xD;
          3. Willing and able to comply with the protocol requirements&#xD;
&#xD;
          4. Able to comprehend and have signed the Informed Consent Form (ICF) to participate in&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participating in another clinical trial for the treatment of cancer at the time of&#xD;
             screening&#xD;
&#xD;
          2. Pregnant or currently breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Memorial Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013 Jun;144(6):1252-61. doi: 10.1053/j.gastro.2013.01.068. Review.</citation>
    <PMID>23622135</PMID>
  </reference>
  <reference>
    <citation>Gachago C, Draganov PV. Pain management in chronic pancreatitis. World J Gastroenterol. 2008 May 28;14(20):3137-48. Review.</citation>
    <PMID>18506917</PMID>
  </reference>
  <reference>
    <citation>Katri KM, Ramadan BA, Mohamed FS. Thoracoscopic splanchnicectomy for pain control in irresectable pancreatic cancer. J Laparoendosc Adv Surg Tech A. 2008 Apr;18(2):199-203. doi: 10.1089/lap.2007.0066.</citation>
    <PMID>18373443</PMID>
  </reference>
  <reference>
    <citation>Jones WB, Jordan P, Pudi M. Pain management of pancreatic head adenocarcinomas that are unresectable: celiac plexus neurolysis and splanchnicectomy. J Gastrointest Oncol. 2015 Aug;6(4):445-51. doi: 10.3978/j.issn.2078-6891.2015.052. Review.</citation>
    <PMID>26261731</PMID>
  </reference>
  <reference>
    <citation>Malec-Milewska MB, Tarnowski W, Ciesielski AE, Michalik E, Guc MR, Jastrzebski JA. Prospective evaluation of pain control and quality of life in patients with chronic pancreatitis following bilateral thoracoscopic splanchnicectomy. Surg Endosc. 2013 Oct;27(10):3639-45. doi: 10.1007/s00464-013-2937-0. Epub 2013 Apr 10.</citation>
    <PMID>23572221</PMID>
  </reference>
  <reference>
    <citation>Davis BR, Vitale M, Lecompte M, Vitale D, Vitale GC. An objective study of pain relief in chronic pancreatitis from bilateral thoracoscopic splanchnicectomy. Am Surg. 2008 Jun;74(6):510-4; discussion 514-5.</citation>
    <PMID>18556993</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Gary C. Vitale, MD</investigator_full_name>
    <investigator_title>Professor of medicine, General Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

